These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20799360)

  • 1. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
    Wood JC; Glynos T; Thompson A; Giardina P; Harmatz P; Kang BP; Paley C; Coates TD
    Am J Hematol; 2010 Oct; 85(10):818-9. PubMed ID: 20799360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.
    Piga A; Longo F; Origa R; Roggero S; Pinna F; Zappu A; Castiglioni C; Cappellini MD
    Br J Haematol; 2014 Nov; 167(3):423-6. PubMed ID: 24976388
    [No Abstract]   [Full Text] [Related]  

  • 4. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK
    Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
    Peng CT; Chang JS; Wang LY; Chiou SS; Hsiao CC; Wang SC; Hung GY; Wu KH
    Hemoglobin; 2009; 33(5):304-11. PubMed ID: 19814676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassemia major patients.
    El Beshlawy A; El Tagui M; Hamdy M; El Ghamrawy M; Azim KA; Salem D; Said F; Samir A; St Pierre T; Pennell DJ
    Ann Hematol; 2014 Mar; 93(3):375-9. PubMed ID: 23949317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
    Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
    Haematologica; 2012 Jun; 97(6):842-8. PubMed ID: 22271905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.
    Wood JC; Kang BP; Thompson A; Giardina P; Harmatz P; Glynos T; Paley C; Coates TD
    Blood; 2010 Jul; 116(4):537-43. PubMed ID: 20421452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
    Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
    Haematologica; 2011 Jan; 96(1):48-54. PubMed ID: 21071497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox: an update.
    Porter JB
    Hemoglobin; 2009; 33 Suppl 1():S70-5. PubMed ID: 20001635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
    Cassinerio E; Roghi A; Orofino N; Pedrotti P; Zanaboni L; Poggiali E; Giuditta M; Consonni D; Cappellini MD
    Ann Hematol; 2015 Jun; 94(6):939-45. PubMed ID: 25563596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
    Pathare A; Taher A; Daar S
    Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Importance of Cardiac T2* Magnetic Resonance Imaging for Monitoring Cardiac Siderosis in Thalassemia Major Patients.
    Chaosuwannakit N; Makarawate P; Wanitpongpun C
    Tomography; 2021 Apr; 7(2):130-138. PubMed ID: 33919601
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined iron chelation therapy.
    Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
    Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.